Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in adu
Biotech stock plays outside of GLP-1 weight-loss market
06:35pm, Thursday, 19'th Sep 2024
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
02:21pm, Monday, 16'th Sep 2024
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and of
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
01:56pm, Wednesday, 11'th Sep 2024
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
07:00am, Wednesday, 11'th Sep 2024
Three new post-hoc analyses highlight EYLEA HD rapid and sustained fluid control and consistent safety profile over two years in patients with wet age-related macular degeneration (wAMD)
Prediction: These 2 Companies Will Split Their Stocks by 2027
06:45am, Wednesday, 11'th Sep 2024
These two drugmakers have been delivering significantly above-average returns for years. Both still have excellent prospects and could decide to split their stocks as their share prices get higher.
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
01:05am, Wednesday, 11'th Sep 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary an
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary e
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
2 Biotech Stocks To Watch In September 2024
09:36pm, Tuesday, 10'th Sep 2024
Here are biotech stocks to check out this month.
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
05:00pm, Monday, 09'th Sep 2024
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
07:00am, Monday, 09'th Sep 2024
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)
05:17pm, Thursday, 05'th Sep 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Wells Fargo 2024 Healthcare Conference September 5, 2024 12:45 PM ET Company Participants Marion McCourt - EVP, Commercial Ryan Crowe - SVP, IR and Strat
